EGFR and non-small cell lung carcinoma: Another Phase III randomized controlled clinical trial, ORIENT‐31, published second interim results showing chemotherapy based on the addition of sintilimab (PD‐1 inhibitor) and IBI305 (bevacizumab biosimilar) was able to provide a significant PFS benefit to patients with EGFR‐TKI progression in non‐squamous NSCLC with EGFR‐mutation, and the benefit continued because the OS endpoint is not achieved in the experimental group.24